This 8th day of August 2023, the Court having held a jury trial and the jury having rendered a unanimous verdict on August 27, 2021 (see D.I. 465), pursuant to Federal Rule of Civil Procedure 58, IT IS HEREBY ORDERED that: 1. Judgment is entered in favor of Plaintiffs ArcherDX, LLC and The General Hospital Corporation (collectively, “Plaintiffs”) that Defendants Qiagen Sciences, LLC, Qiagen LLC, Qiagen Beverly, LLC, Qiagen Gaithersburg, LLC, Qiagen GmbH, and Qiagen N.V. (collectively, “Defendants”) directly infringed claims 16, 17, and 19 of U.S. Patent No. Case 1:18-cv-01019-MN Document 551 Filed 08/08/23 Page 1 of 5 PageID #: 24478 2 10,017,810 (the “’810 Patent”)1 and claims 1, 5, and 19 of U.S. Patent No. 10,450,597 (the “’597 Patent”)2 (collectively, the “Asserted Claims”). 2. Judgment is entered in favor of Plaintiffs that Defendants induced infringement of the Asserted Claims. 3. Judgment is entered in favor of Plaintiffs that Defendants contributed to infringement of the Asserted Claims. 4. Judgment is entered in favor of Plaintiffs that Defendants have not shown invalidity for obviousness, lack of written description, or indefiniteness of the Asserted Claims of the ’810 Patent, nor have Defendants shown invalidity for anticipation, lack of written description, or indefiniteness of the Asserted Claims of the ’597 Patent. 5. Judgment is entered in favor of Plaintiffs and against Defendants for damages in the amount of $841,756.00 caused by Defendants’ sale of RNA-related accused products to customers within the United States and in the amount of $752,006.00 caused by Defendants’ sale of other accused products to customers within the United States.